Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Revance Therapeutics
(NQ:
RVNC
)
3.810
+0.080 (+2.14%)
Streaming Delayed Price
Updated: 1:47 PM EST, Dec 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Revance Therapeutics
< Previous
1
2
3
4
5
6
7
8
9
Next >
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ROIC, PWUP, RVNC on Behalf of Shareholders
November 09, 2024
From
Halper Sadeh LLC
Via
GlobeNewswire
Revance Reports Third Quarter 2024 Financial Results, Provides Corporate Update
November 07, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
“Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments”
October 28, 2024
Via
AB Newswire
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ZUO, ARC, K, RVNC on Behalf of Shareholders
October 18, 2024
From
Halper Sadeh LLC
Via
GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K, RVNC, CPTN on Behalf of Shareholders
October 17, 2024
From
Halper Sadeh LLC
Via
GlobeNewswire
The Law Offices of Frank R. Cruz Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of Investors
October 17, 2024
From
The Law Offices of Frank R. Cruz
Via
Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of Investors
October 15, 2024
From
Law Offices of Howard G. Smith
Via
Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of Investors
October 15, 2024
From
Glancy Prongay & Murray LLP
Via
Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BTTR, RVNC, ARC, RFL on Behalf of Shareholders
September 27, 2024
From
Halper Sadeh LLC
Via
GlobeNewswire
REVANCE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Revance Therapeutics, Inc. - RVNC
August 15, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITI, RVNC, BALY, DRQ on Behalf of Shareholders
August 13, 2024
From
Halper Sadeh LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Revance Therapeutics, Inc. (Nasdaq – RVNC), Greenbrook TMS, Inc. (OTC – GBNHF), R1 RCM Inc. (Nasdaq - RCM), Enstar Group Limited (Nasdaq – ESGR)
August 12, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
RVNC Investigation: Halper Sadeh LLC Is Investigating Whether the Sale of Revance Therapeutics, Inc. Is Fair to Shareholders
August 12, 2024
From
Halper Sadeh LLC
Via
Business Wire
Revance Reports Second Quarter 2024 Financial Results, Provides Corporate Update
August 08, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024
August 01, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 14, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Participate in Upcoming Investor Conferences
May 28, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update
May 09, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical Dystonia
May 09, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024
May 02, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting
April 12, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 27, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Announces Pricing of $100.0 Million Public Offering of Common Stock
March 04, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Announces Proposed Public Offering of Common Stock
March 04, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update
February 28, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024
February 21, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Participate in Upcoming Investor Conferences
February 21, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Receives Permanent J-Code for DAXXIFY® and Announces Publication of DAXXIFY Pivotal Study (ASPEN-1) Results in Neurology®
February 02, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Participate in the Guggenheim 6th Annual Biotechnology Conference
February 01, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook
January 08, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.